Literature DB >> 28462738

Models of antimicrobial pressure on intestinal bacteria of the treated host populations.

V V Volkova1, C L Cazer2, Y T Gröhn2.   

Abstract

Antimicrobial drugs are used to treat pathogenic bacterial infections in animals and humans. The by-stander enteric bacteria of the treated host's intestine can become exposed to the drug or its metabolites reaching the intestine in antimicrobially active form. We consider which processes and variables need to be accounted for to project the antimicrobial concentrations in the host's intestine. Those include: the drug's fraction (inclusive of any active metabolites) excreted in bile; the drug's fractions and intestinal segments of excretion via other mechanisms; the rates and intestinal segments of the drug's absorption and re-absorption; the rates and intestinal segments of the drug's abiotic and biotic degradation in the intestine; the digesta passage time through the intestinal segments; the rates, mechanisms, and reversibility of the drug's sorption to the digesta and enteric microbiome; and the volume of luminal contents in the intestinal segments. For certain antimicrobials, the antimicrobial activity can further depend on the aeration and chemical conditions in the intestine. Model forms that incorporate the inter-individual variation in those relevant variables can support projections of the intestinal antimicrobial concentrations in populations of treated host, such as food animals. To illustrate the proposed modeling framework, we develop two examples of treatments of bovine respiratory disease in beef steers by oral chlortetracycline and injectable third-generation cephalosporin ceftiofur. The host's diet influences the digesta passage time, volume, and digesta and microbiome composition, and may influence the antimicrobial loss due to degradation and sorption in the intestine. We consider two diet compositions in the illustrative simulations. The examples highlight the extent of current ignorance and need for empirical data on the variables influencing the selective pressures imposed by antimicrobial treatments on the host's intestinal bacteria.

Entities:  

Keywords:  Antimicrobial concentration in intestine; antimicrobial pharmacokinetics; antimicrobial resistance; cattle; drug degradation; population pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 28462738      PMCID: PMC9203428          DOI: 10.1017/S095026881700084X

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  49 in total

1.  A compartmental absorption and transit model for estimating oral drug absorption.

Authors:  L X Yu; G L Amidon
Journal:  Int J Pharm       Date:  1999-09-20       Impact factor: 5.875

2.  Effect of wheat and corn variety on fiber digestion in beef steers fed high-grain diets.

Authors:  C Martin; C Philippeau; B Michalet-Doreau
Journal:  J Anim Sci       Date:  1999-08       Impact factor: 3.159

Review 3.  Gastrointestinal transit and drug absorption.

Authors:  Toshikiro Kimura; Kazutaka Higaki
Journal:  Biol Pharm Bull       Date:  2002-02       Impact factor: 2.233

4.  Absorption and excretions studies on tetracycline.

Authors:  M H PINDELL; K M CULL; K M DORAN; H L DICKISON
Journal:  J Pharmacol Exp Ther       Date:  1959-04       Impact factor: 4.030

5.  Use of pharmacokinetic modeling to assess antimicrobial pressure on enteric bacteria of beef cattle fed chlortetracycline for growth promotion, disease control, or treatment.

Authors:  Casey L Cazer; Victoriya V Volkova; Yrjö T Gröhn
Journal:  Foodborne Pathog Dis       Date:  2014-03-03       Impact factor: 3.171

Review 6.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 7.  Human intestinal bacteria as reservoirs for antibiotic resistance genes.

Authors:  Abigail A Salyers; Anamika Gupta; Yanping Wang
Journal:  Trends Microbiol       Date:  2004-09       Impact factor: 17.079

8.  Management of antibiotic residues from agricultural sources: use of composting to reduce chlortetracycline residues in beef manure from treated animals.

Authors:  Osman A Arikan; Walter Mulbry; Clifford Rice
Journal:  J Hazard Mater       Date:  2008-08-15       Impact factor: 10.588

9.  Residue content of beef feedlot manure after feeding diethylstilbestrol, chlortetracycline and Ronnel and the use of stirofos to reduce population of fly larvae in feedlot manure.

Authors:  T S Runsey; R W Miller; D A Dinius
Journal:  Arch Environ Contam Toxicol       Date:  1977       Impact factor: 2.804

10.  Diet shapes the gut microbiome of pigs during nursing and weaning.

Authors:  Steven A Frese; Kent Parker; C Chris Calvert; David A Mills
Journal:  Microbiome       Date:  2015-07-01       Impact factor: 14.650

View more
  4 in total

1.  Monte Carlo Simulations Suggest Current Chlortetracycline Drug-Residue Based Withdrawal Periods Would Not Control Antimicrobial Resistance Dissemination from Feedlot to Slaughterhouse.

Authors:  Casey L Cazer; Lucas Ducrot; Victoriya V Volkova; Yrjö T Gröhn
Journal:  Front Microbiol       Date:  2017-09-20       Impact factor: 5.640

2.  Modeling the Effect of Tylosin Phosphate on Macrolide-Resistant Enterococci in Feedlots and Reducing Resistance Transmission.

Authors:  Gregory Sean Stapleton; Casey L Cazer; Yrjö T Gröhn
Journal:  Foodborne Pathog Dis       Date:  2020-10-02       Impact factor: 3.171

3.  Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers.

Authors:  Derek M Foster; Megan E Jacob; Kyle A Farmer; Benjamin J Callahan; Casey M Theriot; Sophia Kathariou; Natalia Cernicchiaro; Timo Prange; Mark G Papich
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

4.  Faecal concentrations of ceftiofur metabolites in finisher pigs administered intramuscularly with ceftiofur.

Authors:  Tara N Gaire; Jessica Salas; Kara M Dunmire; Chad B Paulk; Mike D Tokach; Tiruvoor G Nagaraja; Victoriya V Volkova
Journal:  Vet Med Sci       Date:  2021-05-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.